Search Results for: Iveric Bio

Eric Stonestreet, ‘Modern Family’ Actor, Joins Forces with Astellas’ Iveric Bio to Launch Vision Health Awareness Initiative

by
Eric Stonestreet Iveric Bio eye diseases, Geographic atrophy age-related macular degeneration, Iveric Bio Izervay FDA approval, Eric Stonestreet family story eye health, Iveric Bio More to See campaign, Geographic atrophy symptoms and progression, Eric Stonestreet AskAboutGA.com website,

Iveric Bio, an Astellas-acquired biotech company, has initiated a compelling awareness campaign for a disease it recently gained FDA approval to treat. In a bid to raise awareness, the company has enlisted the support of two-time Emmy Award-winning actor Eric Stonestreet. Stonestreet, renowned for his role as Cameron Tucker in the ABC sitcom “Modern Family,” … Read more

Astellas’ Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment

by
Astellas' Izervay Shows Prolonged Efficacy in 2-Year Study for Geographic Atrophy Treatment

Astellas made a significant acquisition of Iveric Bio earlier this year, primarily motivated by the potential of Iveric’s geographic atrophy candidate, now known as Izervay. This strategic move aimed to establish Izervay as a pivotal revenue source for the company. New findings presented at the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco … Read more

Astellas claims positive results for Izervay in geographic atrophy but remains vague on data

by
astellas, izervay, geographic atrophy, eye disease, phase 3 trial, primary endpoint, dry AMD

Astellas, having recently secured FDA approval for its drug Izervay to treat geographic atrophy (GA), is now in direct competition with Apellis and its GA treatment, Syfovre, which received FDA approval earlier this year. These two drugs are the only available treatments for GA, a condition that affects approximately 1.5 million individuals in the United … Read more

FDA Approves Izervay for Geographic Atrophy

by
IZERVAY: FDA Approves First Drug for Geographic Atrophy

Source – Astellas Pharma Astellas Pharma has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4, 2023. Izervay is a novel complement C5 inhibitor and is now the only approved treatment for GA with a statistically significant reduction (p<0.01) in … Read more

Pharmtales - your go-to source for comprehensive coverage of the pharmaceutical industry.

pharmtales
Latest Pharma News & Insights

© 2024 pharmtales.com | All rights reserved.

PRIVACY POLICY terms of service Contact us